

Медицински Университет – София

Университетска Болница “Александровска”

Катедра по Дерматология и Венерология

Бул. Г. Софийски 1 София, 1431, тел (02) 952 6191, факс (02) 952 0241

Sofia Medical University

Alexander's University Hospital

Department of Dermatology and Venereology

1, G. Sofiiski str., Sofia, BG-1431, Bulgaria, tel 359 2 9526191, fax 359 2 9520241

Дата/Date 07 May 2002

Изх №/Ref No. RT-042/2002

Attnt: Mr. H. Crede, Crede Natural Oils, RSA

Preliminary Report on Effectiveness of Theraflax

On July 1st, 2001 we have started an investigation of the therapeutic actions of the product Theraflax in patients suffering from psoriasis vulgaris and arthropatic psoriasis. We have investigated total of 52 patients: 38 male and 14 female, aged from 18 to 65 years old, who suffer from chronic resident form of psoriasis. Patients have been followed up for at least 6 months. Before the treatment and on the 6th month the following parameters were laboratory tested: WBC, differential count, Hb, ESR, protein in urine, sugar in urine, urobilinogen in urine, sediment in urine, lipid profile, ASAT, ALAT, □-gpt, alkaline phosphatase, cAMP, cGMP. The product Theraflax is registered as food supplement and contains natural ingredients. All patients were treated with the following dosage: 10 ml in the morning and 10 ml in the evening. Patient's tolerance to the product was very good, only 3 out of total 63 patients dropped out of the study due to the intolerance reasons. Those three patients (2 female and 1 male) were cholecystoectomized. Preliminary data of the investigations shows that the product Theraflax has a regulative action on the parameters of lipid profile and specifically on the total cholesterol level and triglyceride level. No change due to Theraflax is observed on the liver parameters data and urine check ups. Dynamic of the changes of the cyclic nucleotides is interesting – after 6 months therapy they show a tendency towards normalization.

Clinical observation of the patients shows good clinical effect – evident reduction of the psoriatic lesions, reduction of the erythematic and papulo-squamic lesions in 22 patients. Clinical improvement was noted also in 18 patients and in 9 patients no change was recorded. In 3 patients the skin condition has worsened. Of particular interest were 19 patients suffering from arthropatic psoriasis. All of them were treated in the past with Metotrexate with no significant therapeutic effect. 10 patients have received more than 1 g, 9 patients – more than 2 g. With great and pleasant surprise we've noted the positive effect on the pain symptomatic in 18 out of 19 patients. Only in 1 patient, who is suffering from severe form of erythrodermia psoriatica and arthropatic psoriasis, a positive effect was not recorded. Pain intensity was measured according to 100 point scale. Patients reported abating of the pain between 14th and 28th day and no recurrence were noted during 6-months observation period. This result is of particular importance for the dermatological practice as Theraflax is the first therapeutic product with such good therapeutic effect.

Based on this study we recommend Theraflax to be used in the treatment of psoriasis and especially in patients suffering from arthropatic form.

With kind regards,



Dr Emil Iliev, physcian in charge of investigation